Pfizer Challenges Two GSK RSV Vaccine Patents in the U.K.

Pfizer has successfully invalidated two patents held by GSK regarding their RSV vaccine in the United Kingdom. This decision marks a significant development in the competitive landscape for respiratory syncytial virus (RSV) vaccine technology. The patents in question were challenged in the context of Pfizer’s ongoing efforts to enhance its market position in the fight against RSV and related respiratory illnesses. The outcome of this action may influence future research and development in the field, as well as the accessibility of RSV vaccines for patients.